Selection of nucleic acid aptamers targeting tumor cell-surface protein biomarkers

86Citations
Citations of this article
132Readers
Mendeley users who have this article in their library.

Abstract

Aptamers are nucleic acids referred to as chemical antibodies as they bind to their specific targets with high affinity and selectivity. They are selected via an iterative process known as ‘selective evolution of ligands by exponential enrichment’ (SELEX). Aptamers have been developed against numerous cancer targets and among them, many tumor cell-membrane protein biomarkers. The identification of aptamers targeting cell-surface proteins has mainly been performed by two different strategies: protein- and cell-based SELEX, when the targets used for selection were proteins and cells, respectively. This review aims to update the literature on aptamers targeting tumor cell surface protein biomarkers, highlighting potentials, pitfalls of protein- and cell-based selection processes and applications of such selected molecules. Aptamers as promising agents for diagnosis and therapeutic approaches in oncology are documented, as well as aptamers in clinical development.

Author supplied keywords

Cite

CITATION STYLE

APA

Mercier, M. C., Dontenwill, M., & Choulier, L. (2017, June 21). Selection of nucleic acid aptamers targeting tumor cell-surface protein biomarkers. Cancers. MDPI AG. https://doi.org/10.3390/cancers9060069

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free